WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation
NYSE:WST • US9553061055
Current stock price
246.78 USD
-1.34 (-0.54%)
Last:
This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. WST Profitability Analysis
1.1 Basic Checks
- WST had positive earnings in the past year.
- WST had a positive operating cash flow in the past year.
- WST had positive earnings in each of the past 5 years.
- WST had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- WST has a Return On Assets of 11.56%. This is amongst the best in the industry. WST outperforms 92.86% of its industry peers.
- Looking at the Return On Equity, with a value of 15.54%, WST belongs to the top of the industry, outperforming 89.29% of the companies in the same industry.
- WST has a better Return On Invested Capital (14.09%) than 92.86% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for WST is above the industry average of 12.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.56% | ||
| ROE | 15.54% | ||
| ROIC | 14.09% |
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
1.3 Margins
- WST has a better Profit Margin (16.06%) than 85.71% of its industry peers.
- In the last couple of years the Profit Margin of WST has remained more or less at the same level.
- WST has a Operating Margin of 20.53%. This is amongst the best in the industry. WST outperforms 87.50% of its industry peers.
- In the last couple of years the Operating Margin of WST has remained more or less at the same level.
- With a Gross Margin value of 35.91%, WST is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
- WST's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.53% | ||
| PM (TTM) | 16.06% | ||
| GM | 35.91% |
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
2. WST Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so WST is still creating some value.
- WST has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, WST has less shares outstanding
- WST has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 12.82 indicates that WST is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 12.82, WST belongs to the top of the industry, outperforming 98.21% of the companies in the same industry.
- WST has a debt to FCF ratio of 0.44. This is a very positive value and a sign of high solvency as it would only need 0.44 years to pay back of all of its debts.
- WST has a better Debt to FCF ratio (0.44) than 92.86% of its industry peers.
- WST has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of WST (0.06) is better than 66.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.44 | ||
| Altman-Z | 12.82 |
ROIC/WACC1.3
WACC10.83%
2.3 Liquidity
- WST has a Current Ratio of 3.02. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
- WST has a Current ratio (3.02) which is comparable to the rest of the industry.
- A Quick Ratio of 2.34 indicates that WST has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.34, WST is in line with its industry, outperforming 55.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.34 |
3. WST Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 8.00% over the past year.
- Measured over the past years, WST shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.94% on average per year.
- WST shows a small growth in Revenue. In the last year, the Revenue has grown by 6.25%.
- Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
3.2 Future
- Based on estimates for the next years, WST will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.50% on average per year.
- Based on estimates for the next years, WST will show a small growth in Revenue. The Revenue will grow by 5.60% on average per year.
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue Next Year6.04%
Revenue Next 2Y6.1%
Revenue Next 3Y6.43%
Revenue Next 5Y5.6%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. WST Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 33.85, which means the current valuation is very expensive for WST.
- Based on the Price/Earnings ratio, WST is valued a bit cheaper than the industry average as 64.29% of the companies are valued more expensively.
- WST is valuated rather expensively when we compare the Price/Earnings ratio to 25.23, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 30.46, which means the current valuation is very expensive for WST.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of WST indicates a somewhat cheap valuation: WST is cheaper than 62.50% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.51. WST is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.85 | ||
| Fwd PE | 30.46 |
4.2 Price Multiples
- WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 67.86% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, WST is valued a bit cheaper than the industry average as 64.29% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.94 | ||
| EV/EBITDA | 21.56 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
- WST has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.04
PEG (5Y)3.78
EPS Next 2Y11.07%
EPS Next 3Y11.63%
5. WST Dividend Analysis
5.1 Amount
- WST has a yearly dividend return of 0.32%, which is pretty low.
- Compared to an average industry Dividend Yield of 0.12, WST pays a better dividend. On top of this WST pays more dividend than 82.14% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.90, WST's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
5.2 History
- The dividend of WST has a limited annual growth rate of 5.48%.
- WST has paid a dividend for at least 10 years, which is a reliable track record.
- WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
5.3 Sustainability
- WST pays out 12.40% of its income as dividend. This is a sustainable payout ratio.
- WST's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP12.4%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
WST Fundamentals: All Metrics, Ratios and Statistics
NYSE:WST (3/27/2026, 12:30:09 PM)
246.78
-1.34 (-0.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/bmo
Earnings (Next)04-22 2026-04-22/bmo
Inst Owners97.62%
Inst Owner Change-2.08%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap17.79B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (33.31%)
Short Float %3.32%
Short Ratio2.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date04-29 2026-04-29 (0.22)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-6.91%
PT rev (3m)-5.85%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)1.86%
EPS NY rev (1m)3.22%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.85 | ||
| Fwd PE | 30.46 | ||
| P/S | 5.79 | ||
| P/FCF | 37.94 | ||
| P/OCF | 23.57 | ||
| P/B | 5.6 | ||
| P/tB | 5.82 | ||
| EV/EBITDA | 21.56 |
EPS(TTM)7.29
EY2.95%
EPS(NY)8.1
Fwd EY3.28%
FCF(TTM)6.51
FCFY2.64%
OCF(TTM)10.47
OCFY4.24%
SpS42.65
BVpS44.06
TBVpS42.43
PEG (NY)3.04
PEG (5Y)3.78
Graham Number85.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.56% | ||
| ROE | 15.54% | ||
| ROCE | 17.45% | ||
| ROIC | 14.09% | ||
| ROICexc | 18.03% | ||
| ROICexgc | 18.82% | ||
| OM | 20.53% | ||
| PM (TTM) | 16.06% | ||
| GM | 35.91% | ||
| FCFM | 15.25% |
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.44 | ||
| Debt/EBITDA | 0.26 | ||
| Cap/Depr | 166.8% | ||
| Cap/Sales | 9.3% | ||
| Interest Coverage | 2103.33 | ||
| Cash Conversion | 94.07% | ||
| Profit Quality | 94.98% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.34 | ||
| Altman-Z | 12.82 |
F-Score7
WACC10.83%
ROIC/WACC1.3
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.04%
Revenue Next 2Y6.1%
Revenue Next 3Y6.43%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.23%
EBIT Next 3Y19.91%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%
WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ
What is the fundamental rating for WST stock?
ChartMill assigns a fundamental rating of 6 / 10 to WST.
What is the valuation status for WST stock?
ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.
Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?
WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.
Can you provide the financial health for WST stock?
The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.
How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?
The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.